Market Overview:
The global hereditary angioedema therapeutic market size reached US$ 2.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.18% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 2.9 Billion |
Market Forecast in 2032
|
US$ 5.5 Billion |
Market Growth Rate 2024-2032 |
7.18% |
Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to a deficiency of a blood protein. It also leads to fluid leakage due to the constant accumulation of liquids outside the veins of hands, feet, intestinal wall, genitals, face, tongue, and larynx. At present, there is a rise in the demand for hereditary angioedema therapeutics due to the growing advancements in novel therapeutics across the globe.
Hereditary Angioedema Therapeutic Market Trends:
There is presently a considerable increase in the prevalence of HAE among individuals due to a lack of C1 protein. As a result, there is a rise in the demand for HAE therapeutics around the world. This, along with the growing awareness among the masses about the treatment of HAE, represents one of the key factors driving the market. Moreover, key market players are extensively investing in research and development (R&D) activities to enhance orphan drug development. This, coupled with the escalating demand for subcutaneous injections that are highly effective in administering medications, such as insulin, morphine, diacetylmorphine and goserelin, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to facilitate faster diagnosis and provide optimal standards of treatment and care to patients. In line with this, rising incidences of genetic mutations leading to the disorder are positively influencing the market. Besides this, the escalating demand for preventive medical care to avoid future illness and treatment is offering lucrative growth opportunities to industry investors. Apart from this, the burgeoning healthcare industry is bolstering the growth of the market.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hereditary angioedema therapeutic market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug class, treatment type, route of administration and end user.
Breakup by Type:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Type I Hereditary Angioedema
- Type II Hereditary Angioedema
- Type III Hereditary Angioedema
Breakup by Drug Class:
- C1-Esterase Inhibitor
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
Breakup by Treatment Type:
- Prophylaxis Treatment
- On-demand Treatment
Breakup by Route of Administration:
- Intravenous
- Subcutaneous
- Oral
Breakup by End User:
- Hospitals
- Clinics
- Home Healthcare
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Type, Drug Class, Treatment Type, Route of Administration, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |